Denmark’s Novo Nordisk is acquiring New Jersey-based Emisphere Technologies in a deal worth about $1.8 billion.
Novartis AG’s gene therapy Luxturna for blindness is recommended for use on England’s public health service, according to the country’s healthcare cost-effectiveness watchdog NICE.
According to a drug shortage list provided by the U.S. Food and Drug Administration, there have been more than 100 drugs that have faced shortages during 2018.
Immunotherapy – reprogramming the immune system to attack cancer cells – is a rapidly growing and promising field in cancer research and treatment.
Health authorities in England rejected a pricey CAR-T cell therapy from Novartis for adults with blood cancer, two weeks after endorsing Kymriah’s use in children and young people.
Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve the company’s drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS).
A cutting-edge CAR-T cell therapy for otherwise untreatable forms of blood cancer is too expensive to justify its use on Britain’s state-funded health service, the country’s healthcare cost agency NICE said.
Biogen’s muscle disease treatment Spinraza has been deemed too expensive for use on Britain’s state-run health service, even after a price discount offered by the U.S. drugmaker.
Britain’s healthcare watchdog NICE recommended Roche’s medicine Gazyvaro for previously untreated advanced follicular lymphoma patients after initially rejecting the medicine in 2017.
GlaxoSmithKline won U.S. approval for a new and improved shingles vaccine, the second of three key products the drugmaker expects approval for in 2017.